Helix Acquisition Corp. (HLXA) to Combine with Moonlake Immunotherapeutics in $360M Deal

Helix (NASDAQ:HLXA) has entered into a definitive agreement to combine with biotech firm Moonlake at a pre-money valuation of $360 million and a pro forma equity value of $620 million at close. Schweiz, Switzerland-based Moonlake is developing three drugs to treat different forms of psoriasis disorders that are set to enter Phase II trials in
Read More